INQOVI — TAIHO ONCOLOGY, approved 2026-05-13 (NDA212576).
965 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.